Zafgen (ZFGN) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zafgen Reports Second Quarter 2015 Financial Results
August 11, 2015 4:01 PM EDTQuarter Highlighted by Completion of Enrollment in bestPWS Phase 3 Clinical Trial - Six Month Data on Track for Release in Early Q1 2016
On Track to Report Data from Ongoing ZAF-203 Clinical Trial in Severe Obesity Complicated by Type 2 Diabetes in Late 2015/Very Early 2016
Ends Quarter with Cash and Marketable Securities of $220 Million
BOSTON, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq: ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its second quarter... More
